Toggle light / dark theme

Dateline: Listen to this audio documentary on the Educate podcast. Subscribe now.

Molly Woodworth was a kid who seemed to do well at everything: good grades, in the gifted and talented program. But she couldn’t read very well.

“There was no rhyme or reason to reading for me,” she said. “When a teacher would dictate a word and say, ‘Tell me how you think you can spell it,’ I sat there with my mouth open while other kids gave spellings, and I thought, ‘How do they even know where to begin?’ I was totally lost.”

Hamlet Pharma Ltd. is making great progress and has just concluded the first part of a clinical trial in patients with bladder cancer. Drug development often takes many years, due to complex development and approval processes. Based on our extensive prior experience, the drug candidate, Alpha1H, has passed a number of important milestones in a relatively short time and with moderate cost. Alpha1H is natural and is found in breast milk. The trial has shown its effectiveness in dissolving tumors.


The strategic goal of Hamlet Pharma is to develop novel cancer treatments for patients who currently lack therapeutic options. Conducting clinical trials is crucial to reach primary goals such as evaluating the therapeutic window for HAMLET in bladder cancer. We also aim to gain new insights that facilitate the drug development for Alpha1H and the diversification of our activities to include other indications.

This device is 1,000 times more sensitive than other methods at detecting of CTCs in the blood of patients with melanoma, a deadly form of skin cancer.

The Cytophone also has shown the ability to detect CTCs even when the tumor is not identifiable on the skin, either because too small (known as the T0 or TX stage) or after surgical removal, and then to destroy them without harming surrounding blood cells.

The team’s findings titled “In Vivo Liquid Biopsy using Cytophone Platform for Photoacoustic Detection of Circulating Tumor Cells in Melanoma Patients” were published in the June 12 issue of Science Translational Medicine, a prestigious scientific journal published by the American Association for the Advancement of Science.

Designed to explore a metal asteroid that could be the heart of a planet, the Psyche mission is readying for a 2022 launch. After extensive review, NASA Headquarters in Washington has approved the mission to begin the final design and fabrication phase, otherwise known as Phase C. This is when the Psyche team finalizes the system design, develops detailed plans and procedures for the spacecraft and science mission, and completes both assembly and testing of the spacecraft and its subsystems.

“The Psyche team is not only elated that we have the go-ahead for Phase C, more importantly we are ready,” said Principal Investigator Lindy Elkins-Tanton of Arizona State University in Tempe. “With the transition into this new mission phase, we are one big step closer to uncovering the secrets of Psyche, a giant mysterious metallic asteroid, and that means the world to us.”

The mission still has three more phases to clear. Phase D, which will begin sometime in early 2021, includes final spacecraft assembly and testing, along with the August 2022 launch. Phase E, which begins soon after Psyche hits the vacuum of space, covers the mission’s deep-space operations and science collection. Finally, Phase F occurs after the mission has completed its science operations; it includes both decommissioning the spacecraft and archiving engineering and science data.

Almost everyone who has thought seriously about this has said that more automation is likely to lead to more inequality.


The robots. They’re coming for your jobs. All of you.

Long the prediction of futurists and philosophers, the lived reality of technology replacing human work has been a constant feature since the cotton gin, the assembly line and, more recently, the computer.